ALBANY, N.Y., Feb. 17, 2016 /PRNewswire/ -- AMRI
(NASDAQ: AMRI) today announced the appointment of David H. Deming, Managing Partner, TAG
Healthcare Advisors, and Kenneth P.
Hagen, CPA, former tax partner at PricewaterhouseCoopers,
LLP to its Board of Directors. Mr. Deming's board appointment is
effective immediately. Mr. Hagen will join AMRI's board in
May 2016.
"We are very fortunate to have both David and Ken join our
board," says William S. Marth,
President and CEO. "Considering AMRI's growth strategy and rapid
expansion, we believe that David's expertise advising healthcare
companies on financing strategies, mergers and acquisitions and
equity capital raising, coupled with Ken's expertise in tax
structuring, mergers and acquisition, and equity financing,
will be extremely valuable as AMRI continues to grow."
Mr. Deming founded TAG Healthcare Advisors in 2014. Prior
to that, Mr. Deming was Principal at Deming & Co., LLC from
September 2012 to March 2013, and CEO of Dimensional SmartNest LLC,
a customized retirement solution which Mr. Deming developed and
successfully sold to Dimensional Fund Advisors. Previously,
Mr. Deming spent over 27 years at JP Morgan Chase and JP Morgan,
where he led the healthcare investment banking group for twelve
years. He has over 35 years of experience in investment banking,
and has focused on the healthcare industry for over 15 years. Mr.
Deming's board positions also include IRX Therapeutics Inc. and
Sorrento Therapeutics Inc. He has served as a non-executive
Chairman for IRX Therapeutics, a clinical-stage bioresearch
company, since May 2014, and as a
Director for Sorrento Therapeutics, an antibody-centric, clinical
stage biopharmaceutical company, since April 2015. Mr. Deming
graduated from Hobart College with
a BA in Economics with Highest Honors, where he served as Chair of
the Board of Trustees from 2006 to 2012.
Mr. Hagen joined Pricewaterhouse Coopers in 1975 and became a
tax partner in 1986, serving a wide range of pharmaceutical,
industrial and technology clients. Since 2000 and until his
retirement in 2011, Ken was the Partner-in-Charge of PwC's Mergers
and Acquisition tax practice in Philadelphia. In addition, Ken served as
principal tax advisor for over a decade to one of the world's
leaders in generic pharmaceuticals. He also advised other clients
on tax issues associated with large and diverse corporate
transactions. Mr. Hagen is a CPA and holds a BS in Accounting from
Pennsylvania State University and a
Masters in Taxation from Villanova
University.
About AMRI
Albany Molecular Research
Inc. (AMRI) is a global contract research and manufacturing
organization that has been working with the Life Sciences industry
to improve patient outcomes and the quality of life for more than
two decades. With locations in North
America, Europe and Asia, our key business segments
include Discovery and Development Services (DDS), Active
Pharmaceutical Ingredients (API), and Drug Product Manufacturing
(DPM). Our DDS segment provides comprehensive services from hit
identification to IND, including expertise with diverse chemistry,
library design and synthesis, in vitro biology and pharmacology,
drug metabolism and pharmacokinetics, as well as natural products.
API supports the chemical development and cGMP manufacture of
complex API, including potent and cytotoxic compounds, controlled
substances, steroids, hormones, and sterile API. DPM supports
development through commercial scale production of complex
liquid-filled and lyophilized parenterals, sterile suspensions and
ophthalmic formulations.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-appoints-david-h-deming-and-kenneth-p-hagen-to-board-of-directors-300221206.html
SOURCE AMRI